Popular Trials
Popular Filters
Frequently Asked Questions
Introduction to genital herpes
What are the top hospitals conducting genital herpes research?
When it comes to cutting-edge clinical trials in the field of genital herpes, several hospitals are making significant strides. In Birmingham, Alabama, the University of Alabama at Birmingham leads the way with one active trial focused on this condition and a total of three genital herpes trials conducted throughout their history. This renowned institution began its foray into genital herpes research back in 2004, showcasing their dedication to finding solutions for those affected by this sexually transmitted infection.
Meanwhile, on the West Coast, multiple hospitals have recently initiated studies aimed at addressing genital herpes. Noble Clinical Research in Tucson is currently conducting an active trial dedicated to exploring potential treatments for this condition. Similarly, Cedars-Sinai Medical Center/Carbon Health located in Beverly Hills and Artemis Institute for Clinical Research situated in Riverside both have ongoing trials focusing specifically on genital herpes as well.
Additionally joining these efforts is Acclaim Clinical Research based in San Diego where they too are actively involved with a trial centered around combating genital herpes.Their engagement marks yet another promising development within this field that has seen consistent progress over time.
These hospitals' commitment to researching and advancing treatment options for individuals living with genital herpes showcases not only their dedication but also their contribution towards improving quality of life for countless patients worldwide. With new trials being launched regularly across different geographical locations, there is hope that breakthroughs will continue emerging to alleviate the burden caused by this common sexually transmitted infection
Which are the best cities for genital herpes clinical trials?
When it comes to genital herpes clinical trials, several cities are at the forefront of research and development. Miami, Florida; Raleigh, North carolina; Seattle, Washington; Beverly Hills, California; and Kansas City, Missouri all have ongoing studies focusing on potential treatments for the condition. These trials explore various interventions such as mRNA-1608 Dose C and HSVTI formulation (F) 1 - Part II Group among others. Through these efforts, individuals affected by genital herpes have access to cutting-edge research that may lead to improved management strategies and a better quality of life.
Which are the top treatments for genital herpes being explored in clinical trials?
The search for effective genital herpes treatments is an ongoing pursuit in clinical trials. One notable contender is BNT163, currently being explored in one active trial specifically targeting genital herpes. With its recent listing in 2022, this potential treatment holds promise and marks a significant step forward in the fight against this persistent viral infection. Researchers are dedicated to finding effective solutions that can alleviate the burden of genital herpes for individuals worldwide.
What are the most recent clinical trials for genital herpes?
Recent clinical trials offer hope for the treatment of genital herpes, with promising advancements on the horizon. mRNA-1608 Dose C has entered Phase 1 and Phase 2 trials, demonstrating potential as a viable therapeutic option. Another notable trial is BNT163, which has reached Phase 1 and shows promise in its early stages. Additionally, the HSVTI formulation (F) 1 - Part II Group trial is underway in Phase 1, exploring innovative approaches to tackling genital herpes. These ongoing studies signify significant progress towards finding effective treatments for this common viral infection that affects millions worldwide.
What genital herpes clinical trials were recently completed?
Recently, several clinical trials focusing on genital herpes have been concluded, highlighting advancements in the field of treatment. One noteworthy trial was completed by the University of Washington in October 2021. Additionally, a trial sponsored by GlaxoSmithKline ended in September 2021, offering insights into potential therapeutic options for those affected by this sexually transmitted infection. These recent developments underscore ongoing efforts to find effective treatments and improve the lives of individuals living with genital herpes.